Multi-omics Mendelian randomization integrated with single-cell sequencing prioritizes HEBP1 as a candidate mechanistic target for ischemic stroke
Globally, stroke remains the second-leading cause of death and the third-leading contributor to disability, posing a persistent challenge in medical research. We employed an integrative multi-omics approach combining DNA methylation, gene expression, and protein abundance data. Summary-data-based Mendelian randomization (SMR) with HEIDI testing was used to prioritize molecular traits sharing a causal variant with ischemic stroke (IS). Complementary two-sample Mendelian randomization analyses using the inverse-variance weighted (IVW) method, together with colocalization analysis, were also performed. These analyses were supplemented by animal experiments and single-cell sequencing to systematically explore IS-associated genes and therapeutic targets. The integrative analysis prioritized heme-binding protein 1 (HEBP1) as a candidate risk-associated factor. Western blot and qPCR confirmed elevated HEBP1 expression in middle cerebral artery occlusion (MCAO) rat models. Single-cell analysis localized relatively high HEBP1 expression to oligodendrocytes and showed variation along the inferred differentiation trajectory. Immune-metabolic analysis highlighted HEBP1’s role in rejection, complement activation, and cholesterol homeostasis. The Comparative Toxicogenomics Database (CTD) identified 17 chemicals with curated HEBP1 associations, and exploratory docking yielded a predicted score of −5.55 kcal/mol for phenobarbital. Because this modest in silico score and the CTD annotations do not establish direct binding or inhibition, the chemical findings were considered hypothesis-generating. This study prioritizes HEBP1 as a candidate mechanistic mediator of ischemic stroke through convergent multi-omics, single-cell, and animal-model evidence. Cell-specific perturbation, brain-relevant molecular validation, and direct target-engagement studies are required to determine causal direction, safety, and therapeutic tractability before clinical application can be considered.
Authors
- Xinxin Zhang (ORCID: https://orcid.org/0009-0001-4526-884X)
- Xin Wang (ORCID: https://orcid.org/0000-0001-8079-8638)
- Qiao Zhang
- Rong Liu (ORCID: https://orcid.org/0009-0009-6041-3679)
- Yalong Qiu
- Jinhan He
Institutions
- Guangzhou University of Chinese Medicine (CN)
Publication Details
- Journal
- BMC Medical Genomics
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1186/s12920-026-02504-5
- Primary Topic
- Genetic Associations and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00